Clinical trial
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults…
NCT00190931 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190931 |
|---|---|
| Title | A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder |
| Official title | A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | Atomoxetine Hydrochloride, placebo |
| Enrollment | 400 |
| Start date | Nov 1, 2003 |
| Completion | Jul 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 24, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: